American Cyanamid Company

William B Wright, Jr

Andrew S Tomcufcik

Joseph W Marsico, Jr

Jeffery B Press

Jay Donald Albright

Gary H Birnberg

Francis J McEvoy

Jeffrey B Press

Walter E Meyer

Nancy H Eudy

Robert A Hardy, Jr

Joseph W Marsico

Andrews S Tomcufcik

Joseph W Marisco, Jr

This disclosure describes novel esters of (triarylphosphoranylidene)carbamic acid which are useful as diuretic agents.

Esters of (triarylphosphoranylidene)carbamic acid for effecting diuresis

This invention concerns novel 2-heteroarylalkyl-1H-benz[de]isoquinoline-1,3(2H)-diones which are useful as inhibitors of thromboxane synthetase and/or as hypotensive agents in the treatment of hypertension and myocardial ischemia.

2-heteroaryl-alkyl-1H-benz[de]-isoquinoline-1,3(2H)-diones

Novel 3-heteroarylalkyl-4-quinazolinones which are useful as inhibitors of thromboxane synthetase and/or as antihypertensive agents in the treatment of hypertension and myocardial ischemia.

Pharmaceutical methods of using 3-heteroarylalkyl-4-quinazolinones

N-[.omega.(3-pyridinyl)alkyl]benzamides which are useful as inhibitors of thromboxane synthetase enzyme and/or as cardioprotective agents in the prevention of myocardial infarction.

N-[.omega.(3-pyridinyl)alkyl]benzamides, useful as thromboxane

3-heteroarylalkyl-4-quinazolinones

Compounds of the formula: ##STR1## wherein A is a divalent moiety of the formula:

3-heteroalkyl-2,4-quinzaolinediones

Novel 3-heteroarylalkyl-1,2,3-benzotriazin-4(3H)-ones, having the structural formula: ##STR1## wherein A is a divalent moiety of the formula: ##STR2## wherein n is an integer from 3 to 10, inclusive; R.sub.1 and R.sub.2 may be the same or different and may be selected from the group consisting of hydrogen, halogen, trifluoromethyl, alkoxy having from one to four carbon atoms, alkyl having from one to four carbon atoms, nitro and amino; wherein Heteroaryl is ##STR3## wherein R.sub.3 and R.sub.4 may be hydrogen, alkyl having from one to four carbon atoms or phenyl and X is CH or N; together with the pharmaceutically acceptable salts thereof; processes for their preparation and their use in treating prostaglandin-related vascular disorders including ischemic heart disease, transient ischemic attack, thrombosis, migraine and hypertension.

3-imidazolylalkyl-, triazolylalkyl-,

This invention discloses novel N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides which are useful as inhibitors of thromboxane synthetase and/or as antihypertensive agents in the treatment of hypertension and myocardial ischemia.

N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides useful as thromboxane

This invention concerns novel N-[(1H-imidazol-1-yl), (1H-1,2,4-triazol-1-yl) and (3-pyridyl)alkyl]benzenesulfonamides which are useful as inhibitors of thromboxane synthetase enzyme and/or as antihypertensive agents.

N-[(1H-imidazol-1-yl) and

N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas which are inhibitors of thromboxane synthetase enzyme.

N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and

N-[(1H-1,2,4-Triazol-l-yl)alkyl]arylamides which are inhibitors of thromboxane synthetase enzyme.

N-[(1H-1,2,4-Triazol-1-yl)alkyl]-arylamides

This disclosure describes novel N-[.omega.-(1H-imidazol-1-yl)alkyl]arylamides which possess the property of inhibiting the enzyme thromboxane synthetase and are also useful in the treatment of hypertension and myocardial ischemia.

N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical

This invention concerns novel N-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]pyridinecarboxamides which are useful as inhibitors of thromboxane synthetase and/or as hypotensive agents in the treatment of hypertension and myocardial ischemia.

Thromboxane synthetase enzyme inhibiting N-[(1H-imidazol-1-yl) and

Substituted N-[(1H-1,2,4-triazol-1-yl)-alkyl]heteroarylcarboxamides are inhibitors of thromboxane synthetase enzyme.

Substituted N-[(1H-1,2,4-triazol-1-yl)-alkyl]heteroarylcarboxamides

This disclosure describes novel N-[.omega.-(1H-imidazol-1-yl)alkyl]amides which possess the property of inhibiting the enzyme thromboxane synthetase.

Growing community of inventors

Woodcliff Lake, NJ, United States of America

William B Wright, Jr